{"id":"cd79b","name":"CD79b","symbol":"CD79B","route":"/targets/cd79b/","asOf":"2026-09-08","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1699","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000007312","uniprot":"https://www.uniprot.org/uniprotkb/P40259/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P40259","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL3712852","open-targets":"https://platform.opentargets.org/target/ENSG00000007312","civic":"https://civicdb.org/genes/974/summary","oncokb":"https://www.oncokb.org/gene/CD79B","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CD79B","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=CD79B","depmap":"https://depmap.org/portal/gene/CD79B?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000007312-CD79B","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/974","omim":"https://www.omim.org/entry/147245"}],"products":[{"id":"polatuzumab-vedotin","name":"Polatuzumab vedotin","status":"approved","modality":"ADC","route":"/drugs/polatuzumab-vedotin/"}],"trials":[{"id":"polargo","name":"POLARGO","nct":"NCT04182204","phase":"3","status":"positive"},{"id":"sunmo","name":"SUNMO","nct":"NCT05171647","phase":"3","status":"positive"},{"id":"polarix","name":"POLARIX","nct":"NCT03274492","phase":"3","status":"positive"},{"id":"polar-bear","name":"POLAR BEAR","nct":"NCT04332822","phase":"3","status":"active"},{"id":"nct06890884","name":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","nct":"NCT06890884","phase":"2","status":"recruiting"},{"id":"nct04844866","name":"Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients","nct":"NCT04844866","phase":"2","status":"recruiting"},{"id":"nct03671018","name":"A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma","nct":"NCT03671018","phase":"1/2","status":"active"},{"id":"nct03533283","name":"An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","nct":"NCT03533283","phase":"1/2","status":"active"}],"pathways":[],"companies":["roche-genentech"],"keyPapers":["paper-polargo-polatuzumab-r-gemox-dlbcl-jco-2026","paper-polarix-polatuzumab-rchp-nejm-2022","paper-wright-lymphgen-genetic-subtypes-dlbcl-cancer-cell-2020","paper-schmitz-genetics-pathogenesis-dlbcl-nejm-2018","paper-chapuy-molecular-subtypes-dlbcl-nat-med-2018","paper-viardot-blood"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[{"class":"anti-cd20","mechanism":"Loss or down-regulation of CD20","category":"antigen"},{"class":"cd3-bispecific","mechanism":"Loss of the tumour-side antigen","category":"antigen"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}